EPCAM and ovarian carcinoma: This was investigated by Czystowska et al. [11] using SEC and immunoaffinity to enrich for EPCAM positive EVs in patients with ovarian cancer malignant ascites, using these EVs to suppress the proliferation of CD4+ and CD8+ T-cells, compared with EVs obtained from ovarian cyst fluid.